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Abstract
Background: We present the case of a patient with acute human immunodeficiency virus infection and a
thrombotic microangiopathy as the first clinical manifestation, a presentation that has not, to the best of our
knowledge, been previously reported.
Case presentation: A 35-year-old Bolivian man presented with epistaxis and thrombocytopenia. We found
microangiopathic anemia, lymphopenia, elevated lactate dehydrogenase, progressive acute renal failure, negative
direct antiglobulin test, and normal activity of ADAMTS13. An human immunodeficiency virus ELISA test was
negative, with an human immunodeficiency virus viral load of 10,000,000 RNA copies/mL. Antiretroviral therapy and
three sessions of therapeutic plasma exchange were able to control thrombotic microangiopathy.
Conclusions: Hematologic manifestations of human immunodeficiency virus infection are frequent. However, the
debut of acute human immunodeficiency virus infection with thrombotic microangiopathy is a rare event. A high
index of suspicion and early treatment is required.
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Background
In the majority of cases, early human immunodeficiency
virus (HIV) infection is asymptomatic [1]. In those pa-
tients with symptoms a variety of clinical manifestations
may be seen, including hematological alterations. Anemia
and leukopenia can be found in up to 70 % of patients at
some point during the course of this viral infection, while
thrombocytopenia is usually mild and occurs at the begin-
ning of the infection due to lower production and in-
creased platelet destruction rate [2, 3]. Other coagulation
disorders such as antiphospholipid syndrome-associated
thrombosis and protein C and protein S deficiency can
also occur, but infrequently. Thrombotic thrombocytope-
nic purpura (TTP) and thrombotic microangiopathy
(TMA) have been occasionally described in patients with
HIV in advanced stages of infection. However, the debut
of acute HIV infection with TTP or TMA is rare [4]. We
present a case of a patient with acute HIV infection with a
severe TMA and a complete response to therapeutic
plasma exchange (TPE) and antiretroviral therapy (ART).
Case presentation
A 35-year-old previously healthy Bolivian man presented
with continuous epistaxis, fever, fatigue, and sore throat. He
had a history of unprotected sexual activity during the pre-
vious month. A physical examination on admission re-
vealed no major alterations, with the exception of ear, nose,
and throat evaluation that showed an intense mucosal
bleeding without any visible injury and only partial re-
sponse to nasal packing. Laboratory tests showed lympho-
penia, anemia, severe thrombocytopenia, acute renal
failure, lactate dehydrogenase (LDH) twice over normal
value, and hyperbilirubinemia that progressively worsened
during the first week of hospitalization (Table 1). A specific
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hematological study was conducted and schistocytes were
found along with negative direct antiglobulin test (Fig. 1).
TTP was suspected and TPE was promptly initiated on the
fourth day of admission; he reached normal platelet counts
and renal function after three daily TPE procedures. His
disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 (ADAMTS13) level was normal
at day 8 (118 %; normal value 20 to 100 %). Infectious dis-
eases investigations showed a negative ELISA HIV test, but
a plasma HIV viral load of >10 million/RNA copies per mL
and slightly low CD4 cell count (398 cell/uL). We did not
find any opportunistic infections or other viral infections.
Acute HIV infection was diagnosed and ART was started
with tenofovir, emtricitabine, and raltegravir. After a 13-day
hospital stay, he was discharged in good condition without
any further evidence of TMA. A 6-month follow-up
showed he had good tolerance to antiretroviral treatment
and he had normal blood counts and renal function
(Fig. 2).
Discussion
This case demonstrates the wide variation of clinical
manifestations found in patients with early HIV infec-
tion. The most frequent hematological findings in this
condition are changes to peripheral blood cells, al-
though coagulation disorders may also occur. Further-
more, the coexistence of immunological-mediated
thrombocytopenia with TTP has been reported in
chronic HIV infection [5].
Thrombotic manifestations such as serious thrombosis,
TTP, and TMA usually occur in late stages of chronic HIV
infection or in patients with poor adherence to ART [6].
The classic form of TTP is caused by an acquired or her-
editary malfunction/deficit of ADAMTS13, which fails to
cleave the ultra-large multimers of the von-Willebrand fac-
tor (v-WF) and produces classic thrombotic microangio-
pathic anemia and multiorgan failure [7]. On the other
hand, TMA associated with drugs, neoplasia, or infections
has the same features as classic TTP but other mechanisms
lead to thrombosis without ADAMTS13 inhibition. In HIV
Table 1 Laboratory values at diagnosis and follow-up
Day 1 Day 4 Day 8 Day 15 Day 90
Hemoglobin gr/dL 11.4 9.4 11.9 10 11
Leucocytes ×1000 cells/uL 5.6 3.8 6.2 5.2 5.4
Lymphocytes ×1000 cells/uL 0.8 0.9 1.2 1.4 1.8
Platelets ×1000 cells/uL 17 12 90 308 420
Creatinine mg/dL 1.2 1.6 0.8 0.8 0.9
Bilirubin mg/dL 1.33 1.9 1.2 0.8 0.7
Lactate dehydrogenase U/L 600 1800 457 413 300
Schistocytes % 3 4 1 0 0
Fibrinogen mg/dL 325 400 218
ADAMTS13 % 120
Haptoglobin mg/dL 25 80 120
Reference values: hemoglobin 12–16 gr/dL, leucocytes 4.5–11.0/uL,
lymphocytes 1.2–4.5 ×103/uL, platelets 150–400 ×103/uL, creatinine 0.6–1.1
mg/dL, bilirubin 0.6–1.0 mg/dL, lactate dehydrogenase 180–225 U/L,
schistocytes <0.5 %, fibrinogen 200–400 mg/dL, ADAMTS13 >20 %,
haptoglobin 20–200 mg/dL. ADAMTS13 disintegrin and metalloproteinase with
a thrombospondin type 1 motif, member 13
Fig. 1 Peripheral blood smear with microangiopathic anemia (×100
optical microscopy). Scarce platelets and abundant schistocytes,


































































Fig. 2 Chronological schema of clinical and laboratory follow-up
characteristics. Cr creatinine, Hb hemoglobin, LDH lactate dehydrogenase,
PLT platelets, TPE therapeutic plasma exchange
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infection, multiple alterations have been described that can
induce either immune TTP triggered by dysfunctional
ADAMTS13 or TMA generated by diverse conditions such
as alterations to complement proteins, endothelial injury
secondary to cytokines induced by the virus, or endothelial
cell damage directly mediated by viral particles [8]. Because
of these multiple pathological pathways, treatment of pa-
tients with either TTP or TMA associated to HIV should
be directed to rapidly control the viral load, reduce the
virus-induced immunosuppression, and replace the defect-
ive ADAMTS13 and coagulation proteins by TPE.
Miller et al. showed that 12 % of patients diagnosed
with TTP had concomitant HIV infection, and they were
more often found to be at advanced stages of the disease
with profound immunosuppression. In this situation,
there was a clear therapeutic benefit of adding ART in
addition to TPE [9]. However, in the largest cohort of
patients, the Oklahoma Thrombotic Thrombocytopenic
Purpura - Hemolytic Uremic Syndrome (TTP-HUS)
register, only 1.84 % of 326 patients with TTP had HIV
infection and the authors concluded that HIV infection,
similar to other inflammatory conditions, could trigger
acute episodes of TTP in susceptible patients. Moreover,
HIV-induced oncological and infectious disorders could
mimic the clinical features of TTP and must be included
in the differential diagnosis [10].
Our patient’s case is remarkable in some aspects. The
first and perhaps most interesting is that his acute HIV
infection debuted with severe TMA, which to the best of
our knowledge has not been previously reported. Nega-
tive anti-HIV antibodies with a very high HIV viral load
defines acute HIV infection and is characteristically as-
sociated with extremely high viremia. Our patient
emphasized that sexual risk behaviors were recent
events (<1 month), and that bleeding and constitutional
symptoms appeared almost immediately upon pre-
sumed HIV exposure.
In this case, TMA was quickly controlled with TPE
and prompt ART initiation. Although TPE could have
had some role in our patient’s recovery, information is
not available to support use in TMA. In this particular
case, the use of TPE was an extreme action given the se-
verity of the patient’s symptoms. In clinical hematology
practice it is well recognized that TPE is mainly benefi-
cial in cases where TTP coexists with an immune inhibi-
tor of ADAMTS13, and not in non-immune TMA
forms. However, there are several recent reports showing
that TPE and other immunological therapies such as ri-
tuximab and eculizumab may be useful in cases not ne-
cessarily associated with autoimmunity. This effect could
be associated to reposition of other coagulation regula-
tory proteins or modulation of this effect could be asso-
ciatedwith reposition of other coagulation regulatory
proteins or B lymphocytes modulation [11].
Conclusions
We presented an unusual manifestation of acute HIV in-
fection associated with TMA that responded successfully
to TPE and prompt start of ART. In patients with TTP
or TMA, HIV testing must be mandatory. Furthermore,
in patients with known HIV infection, physicians should
be aware of the probability of development of throm-
botic complications including TTP and TMA.
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